[go: up one dir, main page]

PE20091208A1 - DERIVATIVES OF LYSINE SULFONAMIDE AS INHIBITORS OF HIV PROTEASE - Google Patents

DERIVATIVES OF LYSINE SULFONAMIDE AS INHIBITORS OF HIV PROTEASE

Info

Publication number
PE20091208A1
PE20091208A1 PE2008001964A PE2008001964A PE20091208A1 PE 20091208 A1 PE20091208 A1 PE 20091208A1 PE 2008001964 A PE2008001964 A PE 2008001964A PE 2008001964 A PE2008001964 A PE 2008001964A PE 20091208 A1 PE20091208 A1 PE 20091208A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
fluoroalkyl
amino
hiv protease
Prior art date
Application number
PE2008001964A
Other languages
Spanish (es)
Inventor
Craig A Coburn
Joseph P Vacca
Hemaka A Rajapakse
Kristen L G Jones
Philippe G Nantermet
James C Barrow
Keith P Moore
Cory Theberge
Abbas M Walji
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20091208A1 publication Critical patent/PE20091208A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN DERIVADO DE LISINA SULFONAMIDA DE FORMULA (A), DONDE R1 ES ALQUILO C1-C6 O ALQUILO C1-C6 SUSTITUIDO CON CICLOALQUILO C3-C6; R2 ES CH(RJ)-Z; Z ES OH, NH2 O ORP; RJ ES H, ALQUILO C1-C6, FLUOROALQUILO C1-C6, ALQUILO C1-C6 SUSTITUIDO CON CICLOALQUILO C3-C5; RP ES P(O)(OH)2, P(O)(OM)2 O C(O)RQ; M ES UN METAL ALCALINO O ALCALINO TERREO; RQ ES ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6, FLUOROALQUILO C1-C6 O ALQUILO C1-C6 SUSTITUIDO CON CICLOALQUILO C3-C5; R5 ES H, ALQUILO C1-C6, FLUOROALQUILO C1-C6, CICLOALQUILO C3-C5 O ALQUILO C1-C6 SUSTITUIDO CON CICLOALQUILO C3-C5; R5A ES H O ALQUILO C1-C6; XA ES ALQUILO C1-C6, CICLOALQUILO C3-C6, HALOALQUILO C1-C6, ENTRE OTROS; k, m Y n SON UN ENTERO DE 0 A 3; R6 ES (i), (ii), (iii), ENTRE OTROS; XB Y XC SON ALQUILO C1-C6, CICLOALQUILO C3-C6, HALOALQUILO C1-C6, ENTRE OTROS; EL SIMBOLO ASTERISCO REPRESENTA EL PUNTO DE UNION AL RESTO DEL COMPUESTO; R7 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{(1S,5S)-5-[[4-AMINOFENIL)SULFONIL](ISOPROPIL)AMINO]-6-HIDROXI-1-METILHEXIL}-NALFA-(METOXICARBONIL)-BETA-FENIL-L-FENILALNINAMIDA, [(1S)-2-({(5S)-5-[[4-AMINOFENIL)SULFONIL]-((3S)-3-ETILBUTIL)AMINO]-6-HIDROXI-1-METILHEXIL)AMINO)-1-(DIFENILMETIL)-2-OXOETIL]CARBAMATO DE METILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INIHIBIDORES DE LA PROTEASA DEL VIH Y SON UTILES EN EL TRATAMIENTO DE INFECCION POR VIH Y DEL SIDAREFERRED TO A LYSINE SULFONAMIDE DERIVATIVE OF FORMULA (A), WHERE R1 IS C1-C6 ALKYL OR C1-C6 ALKYL SUBSTITUTED WITH C3-C6 CYCLOALKYL; R2 IS CH (RJ) -Z; Z IS OH, NH2 OR ORP; RJ IS H, C1-C6 ALKYL, C1-C6 FLUOROALKYL, C1-C6 ALKYL REPLACED WITH C3-C5 CYCLOALKYL; RP ES P (O) (OH) 2, P (O) (OM) 2 O C (O) RQ; M IS AN ALKALINE METAL OR EARTH ALKALINE; RQ IS C1-C6 ALKYL, C3-C6 CYCLOALKYL, AMONG OTHERS; R3 AND R4 ARE H, C1-C6 ALKYL, C1-C6 FLUOROALKYL OR C1-C6 ALKYL SUBSTITUTED WITH C3-C5 CYCLOALKYL; R5 IS H, C1-C6 ALKYL, C1-C6 FLUOROALKYL, C3-C5 CYCLOALKYL OR C1-C6 ALKYL SUBSTITUTED WITH C3-C5 CYCLOALKYL; R5A IS H OR C1-C6 ALKYL; XA IS C1-C6 ALKYL, C3-C6 CYCLOALKYL, C1-C6 HALOALKYL, AMONG OTHERS; k, m AND n ARE AN INTEGER FROM 0 TO 3; R6 IS (i), (ii), (iii), AMONG OTHERS; XB AND XC ARE C1-C6 ALKYL, C3-C6 CYCLOALKYL, C1-C6 HALOALKYL, AMONG OTHERS; THE ASTERISK SYMBOL REPRESENTS THE POINT OF JOINT TO THE REST OF THE COMPOUND; R7 IS H, C1-C6 ALKYL, C3-C6 CYCLOALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: N - {(1S, 5S) -5 - [[4-AMINOPHENIL) SULFONIL] (ISOPROPYL) AMINO] -6-HYDROXY-1-METHYLHEXYL} -NALFA- (METOXYCARBONYL) -BETA-PHENYL-L- PHENYLALNINAMIDE, [(1S) -2 - ({(5S) -5 - [[4-AMINOPHENYL) SULFONIL] - ((3S) -3-ETHYLBUTYL) AMINO] -6-HYDROXY-1-METHYLHEXYL) AMINO) -1 - (DIPHENYLMETIL) -2-OXOETHYL] METHYL CARBAMATE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INIHIBITORS OF HIV PROTEASE AND ARE USEFUL IN THE TREATMENT OF HIV INFECTION AND AIDS

PE2008001964A 2008-08-12 2008-11-24 DERIVATIVES OF LYSINE SULFONAMIDE AS INHIBITORS OF HIV PROTEASE PE20091208A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18872008P 2008-08-12 2008-08-12

Publications (1)

Publication Number Publication Date
PE20091208A1 true PE20091208A1 (en) 2009-08-28

Family

ID=41665383

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001964A PE20091208A1 (en) 2008-08-12 2008-11-24 DERIVATIVES OF LYSINE SULFONAMIDE AS INHIBITORS OF HIV PROTEASE

Country Status (3)

Country Link
AR (1) AR071258A1 (en)
CL (1) CL2008003492A1 (en)
PE (1) PE20091208A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US12453717B1 (en) 2020-10-28 2025-10-28 Accencio LC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Also Published As

Publication number Publication date
AR071258A1 (en) 2010-06-09
CL2008003492A1 (en) 2009-10-16

Similar Documents

Publication Publication Date Title
PE20120533A1 (en) HEPATITIS C VIRUS INHIBITORS
PE20221339A1 (en) PARP1 INHIBITORS
PE20071061A1 (en) CARBONYL DERIVATIVES AS PEPTIDYL-DEFORMYLASE INHIBITORS (PDF)
PE20080072A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
PE20210128A1 (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THEM
EA200601785A1 (en) CONNECTIONS AND METHODS OF TREATMENT OF DYSLIPIDEMIA
PE20090326A1 (en) HETEROCYCLES COMPOUNDS AS ERK INHIBITORS
MX2021002199A (en) INHIBITORS OF CARDIAC SARCOMERES.
PE20130385A1 (en) DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS
CL2011002016A1 (en) Compounds derived from benzimidazole with inhibitory activity of the function of the ns5a protein encoded by the hepatitis c virus (vhc); pharmaceutical composition that includes them; Useful in the treatment of an infection with the hepatitis c virus (vhc).
CO6541569A2 (en) N1-PIRAZOLOESPIROCETONA ACETIL-COA CARBOXYLASE INHIBITORS
ECSP088184A (en) DERIVATIVES OF BENZOQUINAZOLINE AND ITS USE IN THE TREATMENT OF BONE DISEASES
PE20171341A1 (en) PIRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES
PE20091842A1 (en) PYRROLIDINONES AS GLUCOKINASE ACTIVATORS
ECSP099638A (en) NEW ADENINE COMPOUND
UY29704A1 (en) MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS
PE20090042A1 (en) CYCLOPAMINE ANALOGS
PE20140610A1 (en) DERIVATIVES OF PIPERIDINE 3-SPIROCICLICA AS AGONISTS OF GHRELIN RECEPTORS
EP1615914A4 (en) ANTAGONISTS OF CGRP RECEPTORS
PE20080457A1 (en) MACROCYCLIC OXIMYL COMPOUNDS INHIBITORS OF HEPATITIS C PROTEASES
CY1112859T1 (en) Salted potassium inhibitor of HIV integration
PE20120557A1 (en) COMPOUNDS DERIVED FROM (5R) -10, 10-DIMETHYL-7-AZADISPIRO [3.0.4.1] DECAN-8-CARBOXAMIDE AS INHIBITORS OF HEPATITIS C VIRUS
PE20121526A1 (en) HETEROCYCLIC POLYCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
ATE537170T1 (en) CGRP RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
FD Application declared void or lapsed